Okada RD, Johnson G Ⅲ, Nguyen KN, et al. 99mTc-HL91: “Hot spot” detection of ischemic myocardium in vivo by gamma camera imaging[J]. Circulation, 1998， 97: 2 557-2 566.
[2]
Okada RD, Johnson G Ⅲ, Nguyen KN, et al. 99mTc-HL91: effects of low flow and hypoxia on a new ischemiaavid myocardial imaging agent[J]. Circulation, 1997， 95: 1 892-1 899.
[3]
Cook GJR, Barrington S, Houston S, et al. HL91, a new Tc-99m-labelled agent with potential for identifying tumour hypoxia: correlation with FDG PET[J]. J Nucl Med, 1996，37: 87-88.
[4]
Zhang X, Melo T, Ballinger JR, et al. Studies of 99m-Tc-BnAO(HL91): a non-nitroaromatic coumpound for hypoxic cell detection[J]. Int J Radiation Oncology Biol Phys, 1998，42: 737-740.
[5]
Zhang XG, Melo T, Rauth AM, et al. Cellular accumulation and retention of the technetium-99m-labelled hypoxia markers BRU59-21 and butylene amine oxime[J]. Nucl Med Biol, 2001，28: 949-957.
[6]
Lee BF, Chiu NT, Hsia CC, et al. Accumulation of Tc-99m-HL91 in tumor hypoxia: in vitro cell culture and in vivo tumor model[J]. Kaohsiung J Med Sci, 2008, 24(9): 461-472.
[7]
Ramalingam K, Raju N, Nanjappan P, et al. Synthesis of nitroimidazole substituted 3,3,9,9-tetramethyl-4,8-diazaundecane-2,10-dione dioximes (propylene amine oximes, PnAOs): ligands for technetium-99m complexes with potential for imaging hypoxic tissue[J]. Tetrahedron, 1995, 51: 2 875-2 894.
[8]
Melo T, Duncan J, Ballinger JR, et al. BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors[J]. J Nucl Med, 2000, 41: 169-176.
